NCT00002116已完成1 期
A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 9
研究概览
简要总结
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for refractory mucocutaneous herpes simplex virus disease in AIDS patients. To determine whether topical HPMPC therapy can induce re-epithelialization and healing of refractory mucocutaneous herpes simplex virus disease in AIDS patients. To evaluate the virologic effects of topical HPMPC therapy on herpes simplex virus shedding from refractory lesions.
详细描述
Patients are randomized to receive topical therapy with placebo (vehicle alone) or HPMPC at either 0.3 or 1.0 percent once daily for 5 days. Patients are assessed to day 15; those with no significant toxicity are eligible to receive open-label topical HPMPC for up to 6 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Antiretroviral therapy with AZT, ddI, ddC, or d4T.
- •Oral trimethoprim/sulfamethoxazole.
- •Atovaquone.
- •Fluconazole.
- •Rifabutin.
- •Clarithromycin.
- •Patients must have:
- •HIV seropositivity.
- •Mucocutaneous herpes simplex virus (HSV) infection confirmed by previous viral culture and persisting without improvement despite at least 10 days of acyclovir at a minimum dose of 1 g/day (oral) or 15 mg/kg/day (intravenous).
- •Measurable lesions.
- •Consent of parent or guardian if less than 18 years of age.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Active medical problems sufficient to hinder study compliance or assessment of treatment effect.
- •Concurrent Medication:
- •Acyclovir.
- •Immunomodulators (such as corticosteroids or interferons).
- •Lymphocyte replacement therapy.
- •Biologic response modifiers.
- •Ganciclovir.
- •Foscarnet.
- •Vidarabine.
- •Topical trifluridine.
- •Other investigational drugs (except d4T).
- •Amphotericin.
- •Intravenous therapy for PCP.
- •Chemotherapeutic agents.
- •Prior Medication:
- •Excluded within 14 days prior to study entry:
- •Immunomodulators (such as corticosteroids or interferons).
- •Lymphocyte replacement therapy.
- •Biologic response modifiers.
- •Ganciclovir.
- •Foscarnet.
- •Vidarabine.
- •Topical trifluridine.
- •Other investigational drugs with potential anti-HSV activity.
- •Amphotericin.
- •Intravenous therapy for PCP.
- •Excluded within 4 weeks prior to study entry:
- •Chemotherapeutic agents.
- •At least 10 days of prior acyclovir at a minimum dose of 1 g/day (oral) or 15 mg/kg/day (intravenous).
- •Substance abuse.
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected PatientsCondyloma AcuminataHIV InfectionsNCT00002327Gilead Sciences40
已完成
不适用
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical TrifluridineHerpes SimplexHIV InfectionsNCT00000635National Institute of Allergy and Infectious Diseases (NIAID)25
已完成
1 期
Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)PapillomaNCT00001126National Institute of Allergy and Infectious Diseases (NIAID)36
已完成
2 期
The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCytomegalovirus RetinitisHIV InfectionsNCT00002437Gilead Sciences48
已完成
不适用
A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS PatientsLeukoencephalopathy, Progressive MultifocalHIV InfectionsNCT00000945National Institute of Allergy and Infectious Diseases (NIAID)24